Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) FCF Margin (2016 - 2025)

Historic FCF Margin for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to 4.26%.

  • Harvard Bioscience's FCF Margin rose 121000.0% to 4.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.52%, marking a year-over-year increase of 76500.0%. This contributed to the annual value of 1.28% for FY2024, which is 121800.0% down from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's FCF Margin is 4.26%, which was up 121000.0% from 13.04% recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's FCF Margin registered a high of 16.34% during Q3 2023, and its lowest value of 8.54% during Q1 2022.
  • Moreover, its 5-year median value for FCF Margin was 3.28% (2021), whereas its average is 3.49%.
  • Per our database at Business Quant, Harvard Bioscience's FCF Margin plummeted by -241800bps in 2024 and then skyrocketed by 202400bps in 2025.
  • Over the past 5 years, Harvard Bioscience's FCF Margin (Quarter) stood at 0.73% in 2021, then surged by 1279bps to 8.6% in 2022, then skyrocketed by 43bps to 12.34% in 2023, then plummeted by -53bps to 5.8% in 2024, then decreased by -27bps to 4.26% in 2025.
  • Its last three reported values are 4.26% in Q3 2025, 13.04% for Q2 2025, and 11.36% during Q1 2025.